Barclays
GPCR icon

Barclays’s Structure Therapeutics GPCR Stock Holding History

Barclays’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$233K Sell
7,447
-12,784
-63% -$600K ﹤0.01% 3875
2026
Q2 		$1.09M Buy
20,231
+1,043
+5% +$46.1K ﹤0.01% 2743
2026
Q1 		$925K Buy
19,188
+11,355
+145% +$777K ﹤0.01% 2807
2025
Q4 		$545K Buy
7,833
+4,060
+108% +$166K ﹤0.01% 3794
2025
Q3 		$106K Sell
3,773
-2,555
-40% -$50.9K ﹤0.01% 4595
2025
Q2 		$131K Buy
6,328
+1,016
+19% +$22.3K ﹤0.01% 4500
2025
Q1 		$92K Sell
5,312
-110,359
-95% -$2.7M ﹤0.01% 4438
2024
Q4 		$3.14M Buy
115,671
+34,533
+43% +$1.23M ﹤0.01% 2551
2024
Q3 		$3.56M Buy
81,138
+40,915
+102% +$1.58M ﹤0.01% 2373
2024
Q2 		$1.58M Sell
40,223
-41,039
-51% -$1.69M ﹤0.01% 2305
2024
Q1 		$3.48M Buy
81,262
+80,430
+9,667% +$3.39M ﹤0.01% 2099
2023
Q4 		$33.9K Sell
832
-5,000
-86% -$287K ﹤0.01% 4822
2023
Q3 		$294K Buy
5,832
+4,700
+415% +$151K ﹤0.01% 3096
2023
Q2 		$47.1K Buy
+1,132
New +$31.7K ﹤0.01% 3864

Other funds holding GPCR

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Pacific Heights Asset Management
Pacific Heights Asset Management San Francisco, California $3.1B AUM 37.54% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Exchange Traded Concepts
Exchange Traded Concepts Oklahoma City, Oklahoma $25.3B AUM 51.52% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
TrueMark Investments
TrueMark Investments Chicago, Illinois $856M AUM 21.72% 1-Year Est. Return

Barclays's GPCR Position: Q3 2026 in Review

Barclays reduced its Structure Therapeutics (GPCR) stake by 63% in Q3 2026, selling an estimated $600K and leaving 7,447 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #3875.

Barclays first reported a position in GPCR in Q2 2023 and has held it in 14 quarters since. The position peaked at $3.56M in Q3 2024. 49 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Barclays held 7,447 shares of Structure Therapeutics worth $233K as of Q3 2026.
  • Barclays sold 12,784 Structure Therapeutics shares in Q3 2026, an estimated $600K.
  • Structure Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3875 holding.
  • Barclays first reported a position in Structure Therapeutics in Q2 2023 and has held it in 14 quarters since.
  • Barclays's Structure Therapeutics position peaked at $3.56M in Q3 2024.
  • 49 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.